key: cord-0963564-h11oscbx authors: Nejat, Reza; Sadr, Ahmad Shahir; Freitas, Brendan T.; Crabtree, Jackelyn; Pegan, Scott D.; Tripp, Ralph A.; Najafi, David J. title: Losartan promotes cell survival following SARS-CoV-2 infection in vitro date: 2020-12-28 journal: bioRxiv DOI: 10.1101/2020.12.27.424507 sha: 4b74eb19ec99376061e7c74e44c644635bb31cd4 doc_id: 963564 cord_uid: h11oscbx Introduction Coronavirus disease 2019 (COVID-19) can be associated with mortality and high morbidity worldwide. There is an extensive effort to control infection and disease caused by SARS-CoV-2. This study addressed the hypothesis that angiotensin II type I receptor blocker, Losartan, may restrict pathogenesis caused by SARS-CoV-2 by decreasing viral-induced cytopathological changes by blocking angiotensin II type 1 receptor (AT1R), thus reducing the affinity of the virus for ACE2, and inhibiting papain-like protease of the virus. Method Losartan inhibitory effect on deubiquitination and deISGylation properties of papain-like protease was investigated using a fluorescence method and gel shift analysis determining its inhibitory effects. The inhibitory effect of Losartan on SARS-CoV-2 cell replication was investigated both when losartan was added to the cell culture 1 hour before (pre-infection group) and 1 hour after (post-infection group) SARS-CoV-2 infection of Vero E6 cells. Results Losartan treatment of Vero E6 cells prior to and after SARS-CoV-2 infection reduced SARS-CoV-2 replication by 80% and 70% respectively. Losartan was not a strong deubiquitinase and deISGylase inhibitor of PLpro. Conclusion Losartan added pre- and post-infection to the Vero E6 cell culture significantly prevents cell destruction and replication by SARS-CoV2. Losartan has low side-effects, is readily available, and can be produced at high levels globally, all features of a promising drug in treatment of COVID-19 if validated by clinical trials. The COVID-19 pandemic having with high morbidity and substantial mortality rates has Since its emergence in Wuhan, China, SARS-CoV-2 has infected over 76 million and caused 1.7 million deaths globally according to the World Health Organization (WHO) status report on 23 of December 2020. As a multi-organ disease, COVID-19 involves lungs, cardiovascular system, gastrointestinal tract and the central nervous system. This virus at the genomic level has 79% homology with SARS-CoV [1] [2] [3] [4] . There is currently no effective antiviral drug and currently developed vaccines are not expected to be administered worldwide by the end of 2021. Discovery of a drug that is globally available with antiviral properties and minimum side-effects would significantly impact the management of the pandemic. SARS-CoV-2, like SARS-CoV, uses the ACE2 receptor, a member of renin-angiotensin system, to enter host cells [5] . Binding of the virus spike (S protein) protein, through its receptor binding domain (RBD) in S1 component to ACE2 mediates the cell entry [6] . Inhibition of this process halts infection and disease pathogenesis of COVID-19. Entry of the virus into the host cell initiates its replirrecation. Translation of two open reading frames, (ORF1a/ORF1b) produces two replicase polyproteins (pp1a/pp1ab) [7, 8] . These polyproteins each contain non-structural proteins (nsps) involved in viral replication. Cleavage of these replicases releases 16 nsps through an autoproteolyzing process. Sharing the first 11 nsps, pp1a and pp1ab release nsp1-11 and nsp1-16, respectively [9, 10] . Two cysteine proteases, papain-like protease (PLpro) and 3Chemotrypsin-like proteinase (3CLpro or Mpro), contribute to this proteolysis. PLpro is located in the sequence of nsp3 which separates nsp1/nsp2, nsp2/nsp3 and nsp3/nsp4 while Mpro, embedded in nsp5, separates the nsp4-11 of pp1a and nsp4-16 of pp1ab [10, 11] . Mpro has been shown to reduce induction of type I interferon [12] . In addition, PLpro of SARS-CoV-2, with 83% homology with its counterpart in SARS-CoV, has deubiquinating and deISGylating potential with differing substrates. PLpro of SARS-CoV and SARS-CoV-2 show predominance in cleaving ubiquitin-like interferon-stimulated gene 15 (ISG15) proteins over poly-ubiquitin chains. However, SARS-CoV cleaves ubiquitin more readily than SARS-CoV-2 [13, 14] . These properties modify and suppress the repertoire of host cell proteins and mediators such as IFN-β, ISG15 protein, IRF3, TLR3, TLR4, TLR7 and STING-mediated pathway engaged in innate immunity [14] [15] [16] [17] [18] [19] [20] [21] . It is implied that both PLpro and Mpro influence the immunogenic molecular pathways which allows SARS-CoV-2 to evade recognition by innate immunity system which prolongs its incubation period in host cells. PLpro, of SARS-CoV and SARS-CoV-2, cleaves nsp1, nsp2 and nsp3 at the LXGG sequence of their C-terminals. The LXGG is present in the C-terminus of ubiquitin and ISG15protein [22] [23] [24] . Therefore, iso-and endo-peptidase action of PLpro on suppression of SARS-Cov-2 is a desirable target to suppress its pathogenesis [22] . Inhibition of PLpro deubiquitinating and deISGylating action may prompt the innate immunity against the virus. In the early months of 2020, angiotensin receptor blockers (ARBs) were noted to possibly provide protection against COVID-19 [25] [26] [27] . Stopping the use of ARBs was recommended in the early phase of the pandemic due to the concern over possible increase in viral load [28, 29] . Recent studies have revealed safety of ARBs in patients with COVID-19 [30, 31] . Importantly, a recent study proposed that Losartan, an ARB, could ameliorate complications, especially of acute respiratory distress syndrome (ARDS) associated with COVID-19 [27] . In a previous study, molecular dynamic (MD) analysis showed that Losartan could change the three-dimensional structure of ACE2, preventing establishment of strong bonds between RBD residues of the virus and the residues in ACE2 [27] , and subsequently decrease the affinity of the virus to its receptor. Furthermore, the MD analysis showed that Losartan could change the conformational shape of PLpro by occupying the place for inhibitors of PLpro with high docking energy (Fig.6 ) [27] . This implies that Losartan may act as a PLpro inhibitor. PLpro and PLP2 of other Coronaviruses have been shown to have a substantial impact on the pathogenesis of CoVs [32] [33] [34] [35] . PLpro inhibitors in SARS-CoV-2, have shown to inhibit its replication through suppressing cleavage of nsps [36, 37] . Moreover, these inhibitors prevent PLpro from acting as a deubiquitinase (DUB) or deISGylase, the two properties that enable the virus to evade innate immunity [13, 14] . In addition, as ubiquitins are involved in normal regulatory cellular pathways, deubiquitinating activity of PLpro modifies the host cell environment promoting viral replication [38] . Further work on discoveries of noncovalent inhibitors of PLpro in 2008, which showed them to inhibit viral replication, was aborted soon [14, 39] . Here, we report the very weak inhibitory effect of Losartan against deubiquitinase and deISGylase properties of SARS-CoV-2 PLpro. In this in vitro study of Vero E6 cells, we show that adding Losartan pre-and post-infection with SARS-CoV2 considerably prevents viral replication. Deubiquitinase and deISGylase inhibitory activity of Losartan on SARS-CoV-2 PLpro. To characterize its inhibitory effects on SARS-CoV-2 PLpro, Losartan was incubated at various concentrations with SARS-CoV-2 PLpro and a peptide substrate containing the last five consensus amino acids of ubiquitin (Ub) and interferon stimulated gene product 15 (ISG15) in conjugation with a C-terminal 7-amido-4-methylcoumarin (AMC) fluorogenic reporter group (peptide-AMC). These assays revealed IC 50 value of 1200±61μM for Losartan against peptide-AMC (Table 1) [14] , where the catalytic efficiency of the PLpro for Ub is approximately one-tenth that of ISG15 but more than 250 times that of the peptide-AMC. Therefore, competitive non-covalent inhibitors limit Ub-AMC cleavage at a rate somewhere between those of ISG15-AMC and peptide-AMC. Losartan had an inhibition rate of 2.3% when tested against Ub-AMC (table 1) . Inhibition rate of Losartan was 6.9% against ISG15 cleavage (table 1). These differences between inhibitory rates of Losartan against ISG15-AMC and Ub-AMC are unlikely to have a qualitative difference in a biological system. However, to confirm this, molecular weight shift assays were performed with more biologically accurate substrates ( Fig. 1 ). Effect of Losartan on Tetra-Ub Deubiqutination. Ubl substrates with AMC tags at their C-terminal glycine are not entirely reflective of natural substrates. PLpros have been observed to prefer cleaving poly-Ub chains over mono-Ub substrates [42, 43] . To determine if the inhibition values derived from AMC cleavage assays are reflective of a qualitative change in DUB and deISGylase activity, Losartan was tested against human proISG15 and K48 linked tetra-Ub. As Replication of SARS-CoV-2 depends on PLpro and Mpro functions. Inhibitors of SARS-CoV PLpro, in several studies, have been shown to be as effective against SARS-CoV-2 PLpro [44, 45] . Although many of the findings were promising, the development in introducing effective drugs is lagging. In 2008, discovery of successful antivirals against SARS-CoV was paused after spread of the virus was contained. Discoveries in disease pathogenesis of SARS-CoV-2 can aid in discovery of novel treatments and drugs. One hypothesis proposes that dysregulation in renin-angiotensin system (RAS) components contribute to the cytokine storm in COVID-19. Downregulation of ACE2 during the entry of the virus into the host cells leads to an increase in angiotensin II/angiotensin(1-7) ratio with proinflammatory, pro-apoptotic, destructive and pro-thrombotic effects [27, 46] . In animal studies, it was shown that ACE2 deficiency in mice and infusion of Ang II in swine resulted in corneal inflammatory response and lung pathology, respectively, resembling exactly the immunopathological changes seen in COVID-19 [47, 48] . In an (Fig. 9 ). Note: X-ray crystallography in contrast to NMR analysis and theoretical modeling cannot resolve hydrogen atoms in most protein crystals found in PDB files [49] . Our in vitro study revealed that Losartan was a weak inhibitor of PLpro in cleavage of peptide-AMC (IC50=1200±61μM). It did not substantially suppress deISGylating ability of PLpro (Fig. 2) . It is possible that Losartan interacts with the P3/P4 pocket of PLpro adjacent to its active site and is displaced in the presence of ISG15. This pocket could facilitate cleavage of Ubl substrates by binding the C-terminal of leucine and arginine, of the RLRGG motif, through a protonating reaction in a cleft in the PLpro containing a conserved triad of Histidine(H272)-Cystein(C111)-Aspartic Acid(D286) in papain-like proteases [22, 24, 40] . This is in agreement with the previous bioinformatic findings showing a decrease in the affinity of Losartan for PLpro in the presence of UBl1 (Fig. 7, Fig. 8 ) [27] . It has been reported that SARS-CoV-2 PLpro prefers deISGylation 10 times more than deubiquitination [14] . However, our study demonstrated that Losartan in 2.25mM concentration could completely suppress cleavage of monoubiquitin molecules from polyubiquitin chains by PLpro (Fig.1, Fig. 2 ). Active (cleavage) site of PLpro with its canonical thumb-palm-finger like structure (Fig. 7 ), similar to other cysteine proteases in Coronaviruses, comprises two amino acids, histidine and cysteine, to which aspartic acid is added in the case of SARS-CoV and SARS-CoV-2 [22] . The maximum rate of papain-catalyzing activity occurs in pH of 6.2 where both imidazolium ion (ImH + ) (protonated form of imidazole ring) of histidine and thiolate (deprotonated) form of sulfhydryl group of cysteine are available [50] . Assuming that intracellular pH is near 7 and drops in the context of intracellular ROS overproduction in inflammations like what happens in COVID-19 [27, 51] , active site of PLpro finds a favorable milieu to cleave nsps efficiently. As a general catalytic reaction, papain-like protease thiolate ion of cysteine produces a tetrahedral intermediate by attacking the carbonyl group of the substrate which is then released through protonation by ImH + (Fig. 9 ) [50] . A MD analysis [52] revealed that tertiary structure and folding of PLpro in its cleavage cleft changes cysteine (C111) and histidine (H272) to negatively charged deprotonated cysteine and positively charged doubly protonated histidine, respectively. In this context, negatively charged aspartic acid (D286) aids in stabilization of positively charged histidine (H272) [52] . In fact, imidazole ring is a unique structure in biologic reactions, which by possessing two identical nitrogen atoms, it is responsible for relaying protons from one site to another. If two imidazole rings present closely in the path of proton transfer (ImH + ...Im) an energy barrier may impede the journey of the protons [53] . Accordingly, changes in pH and electrical charge in the catalytic triad of PLpro or presence of any impedance against protonation in the cleavage reaction may distort hydrogen bonds and reduce catalytic efficiency of PLpro in cleavage of nsp1/nsp2, nsp2/nsp3 and nsp3/nsp4 which occurs in c-terminal end of nsp1, nsp2 and nsp3. Losartan approaches the triad with its imidazole ring which may compete and impede proton transfer in making hydrogen bond with the imidazole ring of histidine (Fig. 10) . It is notable that the active site of Mpro of SARS-CoV-2 is composed of a dyad of histidine (H41) and cysteine (C145) to which a water molecule instead of aspartic acid aids in protonation of histidine (H41) [54] . This dyad contributes to cleavage of nsps through the same chemical reaction seen in Figure 9 . Also, imidazole ring of Losartan may disrupt the interaction of histidine and cysteine in this protease. A prior MD analysis [27] demonstrated that Losartan changes the conformational shape of SARS-CoV-2 PLpro. In this study, RMSD graph of 100ns MD simulation of PLpro with and without Losartan shows the changes in the shape of PLpro after 80 ns (Fig. 11 ) [27] . and UBl1 at 6.9% ± 3.4 and 2.3% ± 1.4, respectively (table 1) . Considering the putative effects of Losartan on Ang II/angiotensin(1-7) ratio, and on ACE2 in interaction with SARS-CoV-2 RBD, PLpro and Mpro, we tested the effect of Losartan on cell destruction and replication by SARS-CoV2 in Vero E6 cell culture. Vero E6 cells derived from the kidney of African green monkeys, strongly express ACE2 on their apical membranes as observed in certain cells of the respiratory tract [55] [56] [57] . Additionally, these cells do not produce type I interferons (IFN type I) allowing SARS-CoV and SARS-CoV-2 replication without being recognized by cell innate immunity [58] [59] [60] [61] [62] [63] . According to the results of our Vero E6 cell culture study, which was performed in two-series of triplicated tests, Losartan showed cell protection in both pre-and postinfection groups in a dose dependent manner (p<0.001). Results of clinical trials are expected to be better than in vitro results as Vero E6 cells lack interferon producing ability. Cell destruction in 6-well (number of plaques) and percent of infected cells in 96-well (cells containing nuclear protein) were both reduced significantly (p<0.001) when Losartan was added in increasing concentrations from 0 µM to100 µM by 80% in preinfection and 70% in post-infection groups (Figures 3 and 4) . Based on EC 50 for GRL-0617, a noncovalent inhibitor of PLpro, is reported to be about 27.6 μM [14] . Losartan with EC50 of 7.29 µM in plaque reduction experiment may be more efficient when compared to GRL-0617 in prevention of SARS-CoV2 pathogenesis. The prominent effect of Losartan in pre-infection group is in agreement with a previously published MD analysis revealing a lower affinity of the virus for ACE2 in the presence of Losartan [27] . Furthermore, the cell surviving potential of Losartan might likely be an evidence supporting the previous bioinformatic finding that this drug could change the conformational shape of PLpro or interfere with the interaction of functional residues (histidine, cysteine) in PLpro or Mpro of the virus [27] . In previous studies, Losartan was described to have anti-inflammatory, anti-apoptotic and anti-thrombotic effects through downregulating Ang II mediated AT1R stimulation [27, [64] [65] [66] [67] [68] [69] [70] [71] . Entry of SARS-CoV-2 is associated with downregulation of ACE2 and a subsequent acute rise in Ang II/angiotensin (1-7) ratio with pro-inflammatory, proapoptotic, and prothrombotic outcomes [72] [73] [74] [75] . In order to control SARS-CoV-2induced inflammatory responses, many experts have been trying to extend the half-life of ACE2, given the protective role of ACE2 in COVID-19 [76] . As an alternate to restoring ACE2, Losartan, which rebalances the dysregulated RAS in COVID-19, may attenuate ARDS in patients with COVID-19 [27] . Chemicals and Reagents. Z-RLRGG-7-amino-4-methyl-courmarin (peptide-AMC) was purchased from Bachem. supplemented with 1% heat-inactivated fetal bovine serum [77] . The virus was propagated for 72 hours before it was harvested and the titer determined by plaque assay on Vero E6 cells [78] . The viral plaques were counted and the titer was supplemented with 1% heat-inactivated fetal bovine serum [77] . The virus was propagated for 72 hours before it was harvested and the titer determined by plaque assay on Vero E6 cells [78] . The viral plaques were counted and the titer was determined as PFU/ml. The Vero cells were plated at 5 x 10 5 cells/well in a 6-well plate and incubated overnight at 37ºC. The cells were washed once with PBS once. Losartan was prepared into the following concentrations/well in a separate plate; correlates with viral replication in the infected cells [79] . Average percentage responder intensity of the fluorescent channel from NPs of the virus was measured and the calculations were performed using Prism8 from GraphPad. The manuscript was written through the contributions of all authors. All authors have approved the final version of the manuscript. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging microbes & infections The species severe acute respiratory syndrome related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 Differences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 Coronaviruses: an overview of their replication and pathogenesis, in Coronaviruses The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control The nonstructural proteins directing coronavirus RNA synthesis and processing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response Severe acute respiratory syndrome Coronavirus 2: from gene structure to pathogenic mechanisms and potential therapy Main protease of SARS-CoV-2 serves as a bifunctional molecule in restricting type I interferon antiviral signaling. Signal transduction and targeted therapy Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease SARS Virus Papain-like Protease: A Mysterious Weapon Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and deISGylating activities Activation and evasion of type I interferon responses by SARS-CoV-2 The SARS coronavirus papain like protease can inhibit IRF3 at a post activation step that requires deubiquitination activity SARS coronavirus papain-like protease inhibits the TLR7 signaling pathway through removing Lys63-linked polyubiquitination of TRAF3 and TRAF6. International journal of molecular sciences Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling Ubiquitination and de-ubiquitination: role in regulation of signaling by Toll-like receptors Coronavirus Papain-like Peptidases. 3 ed. Handbook of Proteolytic Enzymes Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme Crystal structure of SARS-CoV-2 papain-like protease Use of angiotensin receptor blockers such as Telmisartan, Losartan in nCoV Wuhan Corona Virus infections-Novel mode of treament Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases Are Losartan and Imatinib Effective Against SARS-CoV2 Pathogenesis? A Pathophysiologic-Based In Silico Study Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19 Coronavirus disease 2019 (covid-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis Murine Coronavirus Ubiquitin-Like Domain Is Important for Papain-Like Protease Stability and Viral Pathogenesis Severe Acute Respiratory Syndrome Coronavirus Papain-Like Protease Ubiquitin-Like Domain and Catalytic Domain Regulate Antagonism of IRF3 and NF-κB Signaling Regulation of IRF-3-dependent Innate Immunity by the Papain-like Protease Domain of the Severe Acute Respiratory Syndrome Coronavirus Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies. bioRxiv Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds Structural view and substrate specificity of papain-like protease from avian infectious bronchitis virus Diversity of ubiquitin and ISG15 specificity among nairoviruses' viral ovarian tumor domain proteases Probing the impact of nairovirus genomic diversity on viral ovarian tumor domain protease (vOTU) structure and deubiquitinase activity Targeting severe acute respiratory syndrome-coronavirus (SARS-CoV-1) with structurally diverse inhibitors: a comprehensive review A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication Pathological role of angiotensin II in severe COVID-19. TH open: companion journal to thrombosis and haemostasis The ACE2-deficient mouse: A model for a cytokine storm-driven inflammation COVID-19 pathophysiology may be driven by a loss of inhibition of the renin-angiotensin-aldosterone system Proteins: structures and molecular properties Amino acids, Peptides and Proteins Intracellular superoxide and hydrogen peroxide concentrations: a critical balance that determines survival or death Assessment of proton-coupled conformational dynamics of SARS and MERS coronavirus papain-like proteases: Implication for designing broad-spectrum antiviral inhibitors Proton transfer properties of imidazole An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus Growth and maintenance of Vero cell lines. Current protocols in microbiology Vero Cells as a Mammalian Cell Substrate for Human Norovirus. Viruses Alpha/beta interferon (IFN-α/β)-independent induction of IFN-λ1 (interleukin-29) in response to Hantaan virus infection Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero) Proliferative growth of SARS coronavirus in Vero E6 cells SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology, in bioRxiv Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses Losartan prevents the development of the pro-inflammatory monocytes CD14+ CD16+ in haemodialysis patients Losartan suppresses the inflammatory response in collagen-induced arthritis by inhibiting the MAPK and NF-κB pathways in B and T cells Losartan attenuates the coronary perivasculitis through its local and systemic anti-inflammatory properties in a murine model of Kawasaki disease Antiapoptotic effect of angiotensin-II type-1 receptor blockade in renal tubular cells of hyperoxaluric rats Antiplatelet effect of losartan and telmisartan in patients with ischemic stroke Antithrombotic effects of losartan in patients with hypertension complicated by atrial fibrillation: 4A (Angiotensin II Antagonist of platelet Aggregation in patients with Atrial fibrillation), a pilot study Mechanisms of the anti-inflammatory actions of the angiotensin type 1 receptor antagonist losartan in experimental models of arthritis Protective effect of losartan and ramipril against stress induced insulin resistance and related complications: Anti-inflammatory mechanisms Angiotensin II revisited: new roles in inflammation, immunology and aging Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications Novel ACE2-IgG1 fusions with improved activity against SARS-CoV2. bioRxiv Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States. Emerging infectious diseases Development and optimization of a direct plaque assay for trypsin-dependent human metapneumovirus strains Identification of host kinase genes required for influenza virus replication and the regulatory role of microRNAs We thank our families and friends for their support which provided us with the time to pursue this endeavor while they endured the challenges that all families have encountered in this pandemic.The humanitarian research in this article was made possible by the University of Georgia College of Pharmacy, Office of Research, College of Veterinary Medicine, and the University of Georgia's Center for Drug Discovery (S.D.P). We thank Derren Barken, PhD for helping with verification of our statistical analysis of the data presented in this research.We thank California Medical Innovations Institute for their reception and encouragement.